Key data
| Regulation | Commission Implementing Decision (EU) 2026/2567 of 19 November 2026 |
|---|---|
| Official reference | OJ:L_202602567 |
| Publication | 20 November 2026 |
| Entry into force | 19 November 2026 |
| Affected substance | Medetomidine |
| Product type | Biocide product type 21 (repulsion or attraction of vertebrates) |
| Legal basis | Regulation (EU) No 528/2012 of the European Parliament and of the Council |
| Affected parties | Manufacturers, distributors and professional users of biocides containing medetomidine |
| Category | European Regulation |
| Year | 2026 |
If your company manufactures, distributes or professionally uses biocides containing medetomidine to control vertebrates, this decision requires you to act immediately. Implementing Decision (EU) 2026/2567, published on 20 November 2026, definitively closes the door to the renewal of this active substance in the European biocide market for type 21 products.
The reason is technical but the consequence is very concrete: insufficient data has been provided to demonstrate the safety and efficacy of medetomidine in accordance with Regulation (EU) No 528/2012. Without that demonstration, the approval cannot be renewed and products containing it must be withdrawn from the market.
What does this regulation establish?
Regulation (EU) No 528/2012 regulates the placing on the market and use of biocides in the European Union. For an active substance to be used in a biocide, it must be approved at European level and that approval must be renewed periodically, providing updated evidence of safety and efficacy.
In the case of medetomidine for biocides of product type 21 — intended to control harmful organisms through the repulsion or attraction of vertebrates — the Commission has concluded that the data provided in the renewal process is insufficient. Therefore, the approval is not renewed.
| Element | Detail |
|---|---|
| Active substance | Medetomidine |
| Type of biocidal product | Type 21: control of harmful organisms by repulsion or attraction of vertebrates |
| Reason for non-renewal | Insufficient data to demonstrate safety and efficacy in accordance with Regulation (EU) 528/2012 |
| Consequence for Member States | Obligation to withdraw authorizations for biocides containing medetomidine for this use |
| Consequence for companies | Limited timeframe to adapt the offer and withdraw stocks from the market |
It is important to emphasize that this decision does not affect other uses of medetomidine outside the scope of biocides of type 21 (for example, veterinary uses), nor biocides of other product types that are not related to the repulsion or attraction of vertebrates.
Economic and operational impact
The consequences for affected companies are direct and on several fronts:
- Withdrawal of national authorizations: Each Member State must revoke the current authorizations of biocides containing medetomidine for product type 21. This means that products currently on the market will lose their legal authorization to be marketed.
- Withdrawal of stocks: Companies will have a limited timeframe — which each Member State will specify in its transposing national regulations — to withdraw affected products from the market. Unsold stocks after that deadline cannot continue to be marketed.
- Portfolio adaptation costs: Manufacturers that have product lines based on medetomidine for vertebrate control will need to reformulate, replace the active substance or discontinue those products.
- Impact on contracts and supplies: Distributors and professional users with supply contracts or committed stock will need to review their agreements and seek authorized alternatives.
- Risk of sanctions: Marketing or professionally using a biocide without current authorization may result in administrative penalties in accordance with the national regulations of each Member State.
Who does it affect?
- Biocide manufacturers that include medetomidine in type 21 products (repellents or attractants for vertebrates).
- Distributors and marketers of these products in the European market.
- Professional users who use biocides containing medetomidine in vertebrate pest control activities (pest control companies, facility managers, agricultural or forestry operations, etc.).
- Procurement and compliance departments of companies that purchase or specify these products in their pest control protocols.
Practical example
Imagine a Spanish pest control company that regularly uses a rodent and bird repellent whose active substance is medetomidine. Until now, that product had national authorization under the European approval of medetomidine for biocide type 21.
With Implementing Decision (EU) 2026/2567 in force since 19 November 2026, the Spanish competent authority must withdraw that national authorization. The pest control company will have a limited timeframe to exhaust or return existing stock and must identify an alternative product with an active substance approved for the same type of use. If it continues to use the product without current authorization, it is exposed to administrative penalties in accordance with Spanish biocide regulations.
The same applies to the manufacturer or distributor that still has units in storage: once the withdrawal deadline has passed, it will not be able to legally market them in any EU Member State.
What should companies do now?
- Identify affected products: Review your own catalog or purchased products to locate all biocides containing medetomidine and classified as product type 21.
- Consult the national competent authority: Contact the national body responsible for biocides (in Spain, the Ministry of Health) to learn the exact deadline for withdrawal of authorizations and stocks that will apply in each Member State.
- Stop new orders and contracts: Do not commit more stock or sign new supply contracts for these products until you have clarity on withdrawal deadlines.
- Search for authorized alternatives: Identify active substances or biocidal products of type 21 that have current approval in accordance with Regulation (EU) 528/2012 and that can replace the affected ones.
- Plan stock withdrawal: Establish an internal plan to manage existing stock within the legal timeframe, including returns to supplier, disposal in accordance with waste regulations or exhaustion before the deadline expires.
- Update internal protocols: If the company has pest control procedures that specify the use of medetomidine, update them to reflect the regulatory change and avoid unauthorized uses.
Frequently asked questions
What is product type 21 in biocides and what products does it include?
Product type 21, according to Regulation (EU) No 528/2012, encompasses biocides intended to control harmful organisms through repulsion or attraction of vertebrates. It includes repellents and attractants for vertebrate animals such as rodents, birds or other animals that may cause damage to facilities, crops or infrastructure. Medetomidine was one of the active substances approved for this use, an approval that is now not being renewed.
When must manufacturers and distributors withdraw medetomidine-containing products from the market?
Implementing Decision (EU) 2026/2567 entered into force on 19 November 2026. From that date, Member States are obliged to withdraw national authorizations for biocides containing medetomidine for product type 21. The specific deadline for withdrawing stocks from the market will be set by each Member State in its national implementing regulations. It is essential to consult the national competent authority to learn that exact deadline.
Why has the approval of medetomidine as a biocide type 21 not been renewed?
According to Implementing Decision (EU) 2026/2567, the reason is that insufficient data has been provided to demonstrate the safety and efficacy of medetomidine in accordance with the criteria required by Regulation (EU) No 528/2012. The European Commission concludes that, without that evidence, it is not possible to renew the approval of the substance for this specific use.
What happens if a company continues to use or sell products containing medetomidine after the authorization is withdrawn?
Marketing or professionally using a biocide without current authorization constitutes a breach of biocide regulations. The specific penalties are established by each Member State in its national legislation, but may include administrative fines, withdrawal of products from the market by order of the competent authority and, in serious cases, criminal liability. It is essential to act within the deadlines set by each country.
Does this ban affect other uses of medetomidine, such as veterinary use?
No. Implementing Decision (EU) 2026/2567 is limited exclusively to the use of medetomidine as an active substance in biocides of product type 21 (repulsion or attraction of vertebrates), under Regulation (EU) No 528/2012. Other uses of medetomidine, such as veterinary or pharmacological uses, are governed by different regulations and are not affected by this decision.
Official source
Consult complete regulation in official source
Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202602567